Mechanisms of thrombosis in paraproteinemias: The effects of immunomodulatory drugs

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 8, 2012, Pages 768-779

  Zangari, Maurizio ^a   Berno, Tamara ^a   Zhan, Fenghuang ^a   Tricot, Guido ^b   Fink, Louis ^c  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c DESERT RESEARCH INSTITUTE   (United States)

Author keywords

immunomodulatory drugs; paraproteinemias; venous thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 8; BORTEZOMIB; CATHEPSIN G; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DEXAMETHASONE; DOXORUBICIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IMMUNOMODULATING AGENT; INTERLEUKIN 6; INTERLEUKIN 8; LENALIDOMIDE; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; RANTES; RAS PROTEIN; SCATTER FACTOR; THALIDOMIDE; THROMBOMODULIN; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VINCRISTINE; VON WILLEBRAND FACTOR;

ACTIVATED PROTEIN C RESISTANCE; ANTIBODY PRODUCTION; BLOOD CLOTTING; CANCER CHEMOTHERAPY; CANCER GROWTH; CARDIOVASCULAR RISK; CELL MATURATION; CELL MEMBRANE; CHRONIC LYMPHATIC LEUKEMIA; DISEASE ASSOCIATION; FIBRINOLYSIS; GENETIC RISK; HUMAN; HYPOXIA; MULTIPLE MYELOMA; NEUTROPENIA; NONHUMAN; PARAPROTEINEMIA; POLYCYTHEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE AGGREGATION; THROMBOCYTE DYSFUNCTION; THROMBOCYTHEMIA; TUMOR GROWTH; VENOUS THROMBOEMBOLISM;

ANIMALS; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE MYELOMA; PARAPROTEINEMIAS; RISK FACTORS; THROMBOSIS;

EID: 84868526939     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1328888     Document Type: Review

References (160)

1. Bennett C. L., Angelotta C., Yarnold P. R., et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA: 2006; 296 21 2558 2560 (Pubitemid 44903859)
2. Rak J., Milsom C., Yu J. Tissue factor in cancer. Curr Opin Hematol: 2008; 15 5 522 528
3. López-Pedrera C., Barbarroja N., Dorado G., Siendones E., Velasco F. Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies. Leukemia: 2006; 20 8 1331 1340 (Pubitemid 44084043)
4. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol: 2004; 24 6 1015 1022
5. Van Den Berg Y. W., Reitsma P. H. Not exclusively tissue factor: neutrophil extracellular traps provide another link between chemotherapy and thrombosis. J Thromb Haemost: 2011; 9 11 2311 2312
6. Contrino J., Hair G., Kreutzer D. L., Rickles F. R. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med: 1996; 2 2 209 215 (Pubitemid 26054985)
7. Kasthuri R. S., Taubman M. B., Mackman N. Role of tissue factor in cancer. J Clin Oncol: 2009; 27 29 4834 4838
8. Rak J. Microparticles in cancer. Semin Thromb Hemost: 2010; 36 8 888 906
9. Morel O., Toti F., Hugel B., et al. Procoagulant microparticles: disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc Biol: 2006; 26 12 2594 2604
10. Versteeg H. H., Ruf W. Emerging insights in tissue factor-dependent signaling events. Semin Thromb Hemost: 2006; 32 1 24 32
11. Giesen P. L., Rauch U., Bohrmann B., et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A: 1999; 96 5 2311 2315 (Pubitemid 29117911)
12. Mackman N. Alternatively spliced tissue factor-one cut too many? Thromb Haemost: 2007; 97 1 5 8
13. Auwerda J. J., Yuana Y., Osanto S., et al. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost: 2011; 105 1 14 20
14. Kakkar A. K., Lemoine N. R., Scully M. F., Tebbutt S., Williamson R. C. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg: 1995; 82 8 1101 1104
15. Uno K., Homma S., Satoh T., et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer: 2007; 96 2 290 295 (Pubitemid 46164734)
16. Wojtukiewicz M. Z., Sierko E., Klement P., Rak J. The hemostatic system and angiogenesis in malignancy. Neoplasia: 2001; 3 5 371 384 (Pubitemid 32988807)
17. White M. C., McHowat J. Protease activation of calcium-independent phospholipase A2 leads to neutrophil recruitment to coronary artery endothelial cells. Thromb Res: 2007; 120 4 597 605 (Pubitemid 47094909)
18. Rong Y., Post D. E., Pieper R. O., Durden D. L., Van Meir E. G., Brat D. J. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res: 2005; 65 4 1406 1413 (Pubitemid 40270169)
19. Yu J. L., May L., Lhotak V., et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood: 2005; 105 4 1734 1741 (Pubitemid 40223697)
20. Boccaccio C., Comoglio P. M. Genetic link between cancer and thrombosis. J Clin Oncol: 2009; 27 29 4827 4833
21. Denko N., Schindler C., Koong A., Laderoute K., Green C., Giaccia A. Epigenetic regulation of gene expression in cervical cancer cells by the tumor microenvironment. Clin Cancer Res: 2000; 6 2 480 487 (Pubitemid 30111467)
22. Ma L., Francia G., Viloria-Petit A., et al. In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. Cancer Res: 2005; 65 12 5365 5373 (Pubitemid 40827350)
23. Falanga A., Barbui T., Rickles F. R. Hypercoagulability and tissue factor gene upregulation in hematologic malignancies. Semin Thromb Hemost: 2008; 34 2 204 210
24. Valsami S., Ruf W., Leikauf M. S., Madon J., Kaech A., Asmis L. M. Immunomodulatory drugs increase endothelial tissue factor expression in vitro. Thromb Res: 2011; 127 3 264 271
25. Cesarman-Maus G., Braggio E., Maldonado H., Fonseca R. Absence of tissue factor expression by neoplastic plasma cells in multiple myeloma. Leukemia 2012 February 15: 10.1038/leu.2012.43 [Epub ahead of print]
26. Dvorak H. F., Quay S. C., Orenstein N. S., et al. Tumor shedding and coagulation. Science: 1981; 212 4497 923 924 (Pubitemid 11120474)
27. Zwicker J. I., Liebman H. A., Neuberg D., et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res: 2009; 15 22 6830 6840
28. Leroyer A. S., Anfosso F., Lacroix R., et al. Endothelial-derived microparticles: biological conveyors at the crossroad of inflammation, thrombosis and angiogenesis. Thromb Haemost: 2010; 104 3 456 463
29. Berckmans R. J., Nieuwland R., Böing A. N., Romijn F. P., Hack C. E., Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost: 2001; 85 4 639 646 (Pubitemid 32293699)
30. Daniel L., Fakhouri F., Joly D., et al. Increase of circulating neutrophil and platelet microparticles during acute vasculitis and hemodialysis. Kidney Int: 2006; 69 8 1416 1423
31. Flaumenhaft R. Formation and fate of platelet microparticles. Blood Cells Mol Dis: 2006; 36 2 182 187
32. Robert S., Poncelet P., Lacroix R., et al. Standardization of platelet-derived microparticle counting using calibrated beads and a Cytomics FC500 routine flow cytometer: a first step towards multicenter studies? J Thromb Haemost: 2009; 7 1 190 197
33. Mobarrez F., Antovic J., Egberg N., et al. A multicolor flow cytometric assay for measurement of platelet-derived microparticles. Thromb Res: 2010; 125 3 e110 e116
34. Shah M. D., Bergeron A. L., Dong J. F., López J. A. Flow cytometric measurement of microparticles: pitfalls and protocol modifications. Platelets: 2008; 19 5 365 372
35. Gelderman M. P., Simak J. Flow cytometric analysis of cell membrane microparticles. Methods Mol Biol: 2008; 484 79 93
36. van Doormaal F. F., Kleinjan A., Di Nisio M., Büller H. R., Nieuwland R. Cell-derived microvesicles and cancer. Neth J Med: 2009; 67 7 266 273
37. Zahra S., Anderson J. A., Stirling D., Ludlam C. A. Microparticles, malignancy and thrombosis. Br J Haematol: 2011; 152 6 688 700
38. Sinauridze E. I., Kireev D. A., Popenko N. Y., et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost: 2007; 97 3 425 434 (Pubitemid 46437805)
39. Horstman L. L., Jy W., Jimenez J. J., Bidot C., Ahn Y. S. New horizons in the analysis of circulating cell-derived microparticles. Keio J Med: 2004; 53 4 210 230 (Pubitemid 40139594)
40. Reininger A. J., Heijnen H. F., Schumann H., Specht H. M., Schramm W., Ruggeri Z. M. Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress. Blood: 2006; 107 9 3537 3545
41. Tesselaar M. E., Osanto S. Risk of venous thromboembolism in lung cancer. Curr Opin Pulm Med: 2007; 13 5 362 367 (Pubitemid 47472294)
42. Hron G., Kollars M., Weber H., et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost: 2007; 97 1 119 123 (Pubitemid 46242392)
43. Key N. S., Kwaan H. C. Microparticles in thrombosis and hemostasis. Semin Thromb Hemost: 2010; 36 8 805 806
44. Zwicker J. I., Furie B. C., Furie B. Cancer-associated thrombosis. Crit Rev Oncol Hematol: 2007; 62 2 126 136 (Pubitemid 46575277)
45. Manly D. A., Wang J., Glover S. L., et al. Increased microparticle tissue factor activity in cancer patients with venous thromboembolism. Thromb Res: 2010; 125 6 511 512
46. Palumbo A., Boccadoro M. A new standard of care for elderly patients with myeloma. Lancet: 2007; 370 9594 1191 1192 (Pubitemid 47503289)
47. Zangari M., Barlogie B., Anaissie E., et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol: 2004; 126 5 715 721 (Pubitemid 39221309)
48. Johnson D. C., Corthals S., Ramos C., et al. Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood: 2008; 112 13 4924 4934
49. Almasi M., Sevcikova S., Slaby O., et al. Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide. Clin LymphomaMyeloma Leuk: 2011; 11 414 420
50. Hussein M. A. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb Haemost: 2006; 95 6 924 930 (Pubitemid 43933748)
51. Blom J. W., Doggen C. J., Osanto S., Rosendaal F. R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA: 2005; 293 6 715 722 (Pubitemid 40216041)
52. Elice F., Fink L., Tricot G., Barlogie B., Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol: 2006; 134 4 399 405 (Pubitemid 44079553)
53. Asosingh K., De Raeve H., de Ridder M., et al. Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression. Haematologica: 2005; 90 6 810 817 (Pubitemid 40897223)
54. Hu J., Handisides D. R., Van Valckenborgh E., et al. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood: 2010; 116 9 1524 1527
55. Colla S., Storti P., Donofrio G., et al. Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells. Leukemia: 2010; 24 11 1967 1970
56. Martin S. K., Diamond P., Williams S. A., et al. Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica: 2010; 95 5 776 784
57. Giatromanolaki A., Bai M., Margaritis D., et al. Hypoxia and activated VEGF/receptor pathway in multiple myeloma. Anticancer Res: 2010; 30 7 2831 2836
58. Löfstedt T., Fredlund E., Holmquist-Mengelbier L., et al. Hypoxia inducible factor-2 alpha in cancer. Cell Cycle: 2007; 6 8 919 926 (Pubitemid 46658746)
59. Patel S. A., Simon M. C. Biology of hypoxia-inducible factor-2 alpha in development and disease. Cell Death Differ: 2008; 15 4 628 634 (Pubitemid 351405065)
60. Parmar K., Mauch P., Vergilio J. A., Sackstein R., Down J. D. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA: 2007; 104 13 5431 5436 (Pubitemid 47175697)
61. Zhang J., Sattler M., Tonon G., et al. Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1 alpha-dependent pathway in multiple myeloma. Cancer Res: 2009; 69 12 5082 5090
62. Kaluz S., Kaluzová M., Stanbridge E. J. Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1 alpha C-terminal activation domain. Mol Cell Biol: 2006; 26 15 5895 5907 (Pubitemid 44134343)
63. Shin D. H., Chun Y. S., Lee D. S., Huang L. E., Park J. W. Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood: 2008; 111 6 3131 3136
64. Lu L., Payvandi F., Wu L., et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res: 2009; 77 2 78 86
65. Watanabe K., Koizumi T., Ruan Z., Kubo K., Sakai A., Shibamoto T. Reduced pulmonary vascular reactivity after cold exposure to acute hypoxia: a role of nitric oxide (NO). High Alt Med Biol: 2007; 8 1 43 49 (Pubitemid 46587447)
66. Lévesque J. P., Winkler I. G., Hendy J., et al. Hematopoietic progenitor cell mobilization results in hypoxia with increased hypoxia-inducible transcription factor-1 alpha and vascular endothelial growth factor A in bone marrow. Stem Cells: 2007; 25 8 1954 1965 (Pubitemid 47258173)
67. Birchmeier C., Birchmeier W., Gherardi E., Vande Woude G. F. Met, metastasis, motility and more. Nat Rev Mol Cell Biol: 2003; 4 12 915 925 (Pubitemid 37493640)
68. Comoglio P. M., Giordano S., Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov: 2008; 7 6 504 516 (Pubitemid 351767118)
69. Pennacchietti S., Michieli P., Galluzzo M., Mazzone M., Giordano S., Comoglio P. M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell: 2003; 3 4 347 361 (Pubitemid 38340304)
70. Boccaccio C., Sabatino G., Medico E., et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature: 2005; 434 7031 396 400 (Pubitemid 40469184)
71. Erickson L. A., Fici G. J., Lund J. E., Boyle T. P., Polites H. G., Marotti K. R. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature: 1990; 346 6279 74 76
72. Kohler H. P., Grant P. J. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med: 2000; 342 24 1792 1801 (Pubitemid 30390240)
73. Smith W. L., DeWitt D. L., Garavito R. M. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem: 2000; 69 145 182
74. Mahtouk K., Tjin E. P., Spaargaren M., Pals S. T. The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas. Biochim Biophys Acta: 2010; 1806 2 208 219
75. Alexandrakis M. G., Passam F. H., Sfiridaki A., Kandidaki E., Roussou P., Kyriakou D. S. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity. Am J Hematol: 2003; 72 4 229 233 (Pubitemid 36383972)
76. Seidel C., Borset M., Turesson I., et al. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. Blood: 1998; 91 3 806 812 (Pubitemid 28078282)
77. Seidel C., Lenhoff S., Brabrand S., et al. Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy. Br J Haematol: 2002; 119 3 672 676 (Pubitemid 35366207)
78. Pour L., Svachova H., Adam Z., et al. Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response. Ann Hematol: 2010; 89 4 385 389
79. Ludek P., Hana S., Zdenek A., et al. Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration. Eur J Haematol: 2010; 84 4 332 336
80. Pour L., Svachova H., Adam Z., et al. Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma. Neoplasma: 2010; 57 1 29 34
81. Börset M., Hjorth-Hansen H., Seidel C., Sundan A., Waage A. Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood: 1996; 88 10 3998 4004 (Pubitemid 26383124)
82. Zhan F., Hardin J., Kordsmeier B., et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood: 2002; 99 5 1745 1757 (Pubitemid 34533050)
83. Takai K., Hara J., Matsumoto K., et al. Hepatocyte growth factor is constitutively produced by human bone marrow stromal cells and indirectly promotes hematopoiesis. Blood: 1997; 89 5 1560 1565 (Pubitemid 27097448)
84. Neben K., Moehler T., Kraemer A., et al. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol: 2001; 115 3 605 608 (Pubitemid 34015650)
85. Dmoszyska A., Roliski J., Bojarska-Junak A., et al. Influence of thalidomide on Bcl2 expression and proangiogenic cytokine levels in short-term culture of peripheral blood and bone marrow mononuclear cells of multiple myeloma patients. Pol J Pharmacol: 2001; 53 6 709 713
86. Rosiñol L., Cibeira M. T., Segarra M., et al. Response to thalidomide in multiple myeloma: impact of angiogenic factors. Cytokine: 2004; 26 4 145 148 (Pubitemid 38624626)
87. Kumar R., Yoneda J., Bucana C. D., Fidler I. J. Regulation of distinct steps of angiogenesis by different angiogenic molecules. Int J Oncol: 1998; 12 4 749 757 (Pubitemid 28133565)
88. Anderson K. L., Smith K. A., Conners K., McKercher S. R., Maki R. A., Torbett B. E. Myeloid development is selectively disrupted in PU.1 null mice. Blood: 1998; 91 10 3702 3710 (Pubitemid 28225738)
89. Selak M. A., Chignard M., Smith J. B. Cathepsin G is a strong platelet agonist released by neutrophils. Biochem J: 1988; 251 1 293 299
90. Pidard D., Renesto P., Berndt M. C., Rabhi S., Clemetson K. J., Chignard M. Neutrophil proteinase cathepsin G is proteolytically active on the human platelet glycoprotein Ib-IX receptor: characterization of the cleavage sites within the glycoprotein Ib alpha subunit. Biochem J: 1994; 303 489 498 (Pubitemid 24317330)
91. Si-Tahar M., Renesto P., Falet H., Rendu F., Chignard M. The phospholipase C/protein kinase C pathway is involved in cathepsin G-induced human platelet activation: comparison with thrombin. Biochem J: 1996; 313 Pt 2 401 408 (Pubitemid 26030126)
92. Gale A. J., Rozenshteyn D. Cathepsin G, a leukocyte protease, activates coagulation factor VIII. Thromb Haemost: 2008; 99 1 44 51
93. Pal R., Monaghan S. A., Hassett A. C., et al. Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood: 2010; 115 3 605 614
94. Stirling D., Hannant W. A., Ludlam C. A. Transcriptional activation of the factor VIII gene in liver cell lines by interleukin-6. Thromb Haemost: 1998; 79 1 74 78 (Pubitemid 28037061)
95. Stouthard J. M., Levi M., Hack C. E., et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost: 1996; 76 5 738 742 (Pubitemid 26388179)
96. Amrani D. L., Christensen C., Hauerwas L., et al. Hemostatic evaluation of Sarns/3M-VAD implantation in calves. ASAIO Trans: 1991; 37 3 M308 M310
97. Neuman M. G., Benhamou J. P., Bourliere M., et al. Serum tumour necrosis factor-alpha and transforming growth factor-beta levels in chronic hepatitis C patients are immunomodulated by therapy. Cytokine: 2002; 17 2 108 117
98. Cermak J., Key N. S., Bach R. R., Balla J., Jacob H. S., Vercellotti G. M. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood: 1993; 82 2 513 520 (Pubitemid 23206115)
99. Begbie M., Notley C., Tinlin S., Sawyer L., Lillicrap D. The Factor VIII acute phase response requires the participation of NFkappaB and C/EBP. Thromb Haemost: 2000; 84 2 216 222 (Pubitemid 30601466)
100. Moore K. L., Andreoli S. P., Esmon N. L., Esmon C. T., Bang N. U. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest: 1987; 79 1 124 130 (Pubitemid 17232509)
101. Zangari M., Saghafifar F., Mehta P., Barlogie B., Fink L., Tricot G. The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost: 2003; 29 3 275 282
102. Coppola A., Tufano A., Di Capua M., Franchini M. Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Semin Thromb Hemost: 2011; 37 8 929 945
103. Yaci M., Sucak G. T., Haznedar R. Fibrinolytic activity in multiple myeloma. Am J Hematol: 2003; 74 4 231 237 (Pubitemid 37484690)
104. Zangari M., Elice F., Fink L., Tricot G. Thrombosis in multiple myeloma. Expert Rev Anticancer Ther: 2007; 7 3 307 315 (Pubitemid 46488336)
105. van Marion A. M., Auwerda J. J., Lisman T., et al. Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. Leuk Res: 2008; 32 7 1078 1084
106. Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet: 2000; 355 9200 248 250 (Pubitemid 30068513)
107. Barillé S., Bataille R., Amiot M. The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma. Eur Cytokine Netw: 2000; 11 4 546 551 (Pubitemid 32044237)
108. Chanan-Khan A. A., Cheson B. D. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol: 2008; 26 9 1544 1552
109. Ramsay A. G., Gribben J. G. Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug. Haematologica: 2009; 94 9 1198 1202
110. Aue G., Nelson Lozier J., Tian X., et al. Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia. Am J Hematol: 2011; 86 10 835 840
111. Dmoszynska A., Podhorecka M., Manko J., Bojarska-Junak A., Rolinski J., Skomra D. The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma. Neoplasma: 2005; 52 2 175 181
112. Eby C. Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. Br J Haematol: 2009; 145 2 151 163
113. DiMinno G., Coraggio F., Cerbone A. M., et al. A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. J Clin Invest: 1986; 77 1 157 164 (Pubitemid 16101214)
114. Knop S., Gerecke C., Liebisch P., et al. Lenalidomide, Adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood: 2009; 113 18 4137 4143
115. Baz R., Li L., Kottke-Marchant K., et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc: 2005; 80 12 1568 1574 (Pubitemid 41747058)
116. Rajkumar S. V., Hayman S. R., Lacy M. Q., et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood: 2005; 106 13 4050 4053 (Pubitemid 41775908)
117. Palumbo A., Falco P., Corradini P., et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMAItalian Multiple Myeloma Network. J Clin Oncol: 2007; 25 28 4459 4465 (Pubitemid 350063804)
118. Landolfi R., Cipriani M. C., Novarese L. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention. Best Pract Res Clin Haematol: 2006; 19 3 617 633 (Pubitemid 43863144)
119. Hassan A. A., Kroll M. H. Acquired disorders of platelet function. Hematology Am Soc Hematol Educ Prog: 2005; 403 408
120. Gabriel D. A., Muga K., Boothroyd E. M. The effect of fibrin structure on fibrinolysis. J Biol Chem: 1992; 267 34 24259 24263
121. Lopaciuk S., Bykowska K., McDonagh J. M., et al. Difference between type I autoimmune inhibitors of fibrin stabilization in two patients with severe hemorrhagic disorder. J Clin Invest: 1978; 61 5 1196 1203 (Pubitemid 8324144)
122. Ideguchi H., Suehiro T., Ohike M., et al. Impaired fibrin formation in a patient with multiple myeloma presenting the "gelationo" phenomenon. Nippon Ketsueki Gakkai Zasshi: 1988; 51 1 109 117
123. Lackner H., Hunt V., Zucker M. B., Pearson J. Abnormal fibrin ultrastructure, polymerization, and clot retraction in multiple myeloma. Br J Haematol: 1970; 18 6 625 636
124. Cohen I., Amir J., Ben-Shaul Y., Pick A., De Vries A. Plasma cell myeloma associated with an unusual myeloma protein causing impairment of fibrin aggregation and platelet function in a patient with multiple malignancy. Am J Med: 1970; 48 6 766 776
125. Davey F. R., Gordon G. B., Boral L. I., Gottlieb A. J. Gamma globulin inhibition of fibrin clot formation. Ann Clin Lab Sci: 1976; 6 1 72 77
126. Kotlín R., Sobotková A., Riedel T., et al. Acquired dysfibrinogenemia secondary to multiple myeloma. Acta Haematol: 2008; 120 2 75 81
127. Sugai S. IgA pyroglobulin, hyperviscosity syndrome and coagulation abnormality in a patient with multiple myeloma. Blood: 1972; 39 2 224 237
128. Baglin T. The measurement and application of thrombin generation. Br J Haematol: 2005; 130 5 653 661 (Pubitemid 43906639)
129. Pabinger I., Ay C. Biomarkers and venous thromboembolism. Arterioscler Thromb Vasc Biol: 2009; 29 3 332 336
130. Hemker H. C., Al Dieri R., De Smedt E., Béguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost: 2006; 96 5 553 561 (Pubitemid 44782533)
131. Petropoulou A. D., Gerotziafas G. T., Samama M. M., Hatmi M., Rendu F., Elalamy I. In vitro study of the hypercoagulable state in multiple myeloma patients treated or not with thalidomide. Thromb Res: 2008; 121 4 493 497 (Pubitemid 351174267)
132. Esmon C. T. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem: 1989; 264 9 4743 4746 (Pubitemid 19092874)
133. Marchant R. E., Kang I., Sit P. S., et al. Molecular views and measurements of hemostatic processes using atomic force microscopy. Curr Protein Pept Sci: 2002; 3 3 249 274 (Pubitemid 34600930)
134. Corso A., Lorenzi A., Terulla V., et al. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol: 2004; 83 9 588 591 (Pubitemid 39209183)
135. Zappasodi P., Mangiacavalli S., Terulla V., et al. Thrombomodulin levels are not modified during thalidomide treatment. Eur J Haematol: 2006; 77 5 453 454 (Pubitemid 44483952)
136. Cini M., Zamagni E., Valdré L., et al. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. Eur J Haematol: 2010; 84 6 484 492
137. Kaushal V., Kaushal G. P., Melkaveri S. N., Mehta P. Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. J Thromb Haemost: 2004; 2 2 327 334 (Pubitemid 40186049)
138. Ingram G. I., Kingston P. J., Leslie J., Bowie E. J. Four cases of acquired von Willebrand's syndrome. Br J Haematol: 1971; 21 2 189 199
139. Buchanan G. R., Handin R. I. Platelet function in the Chediak-Higashi syndrome. Blood: 1976; 47 6 941 948
140. Franchini M., Targher G., Lippi G. Prophylaxis in von Willebrand disease. Ann Hematol: 2007; 86 10 699 704 (Pubitemid 47337931)
141. Tiede A., Priesack J., Werwitzke S., et al. Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study. J Thromb Haemost: 2008; 6 4 569 576 (Pubitemid 351404923)
142. Federici A. B., Budde U., Rand J. H. Acquired von Willebrand syndrome 2004: international registrydiagnosis and management from online to bedside. Hamostaseologie: 2004; 24 1 50 55 (Pubitemid 38233047)
143. Michiels J. J., Budde U., van der Planken M., van Vliet H. H., Schroyens W., Berneman Z. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Best Pract Res Clin Haematol: 2001; 14 2 401 436 (Pubitemid 32677087)
144. Scrobohaci M. L., Daniel M. T., Levy Y., Marolleau J. P., Brouet J. C. Expression of GpIb on plasma cells in a patient with monoclonal IgG and acquired von Willebrand disease. Br J Haematol: 1993; 84 3 471 475 (Pubitemid 23224164)
145. Eikenboom J. C., van der Meer F. J., Briët E. Acquired von Willebrand's disease due to excessive fibrinolysis. Br J Haematol: 1992; 81 4 618 620
146. Shinagawa A., Kojima H., Berndt M. C., et al. Characterization of a myeloma patient with a life-threatening hemorrhagic diathesis: presence of a lambda dimer protein inhibiting shear-induced platelet aggregation by binding to the A1 domain of von Willebrand factor. Thromb Haemost: 2005; 93 5 889 896 (Pubitemid 40691546)
147. van Genderen P. J., Vink T., Michiels J. J., van 't Veer M. B., Sixma J. J., van Vliet H. H. Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen. Blood: 1994; 84 10 3378 3384 (Pubitemid 24352900)
148. Dahlbäck B., Carlsson M., Svensson P. J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA: 1993; 90 3 1004 1008 (Pubitemid 23053939)
149. Bertina R. M., Koeleman B. P., Koster T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature: 1994; 369 6475 64 67 (Pubitemid 24144355)
150. Rees M. M., Rodgers G. M. Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. Thromb Res: 1993; 71 5 337 359 (Pubitemid 23244324)
151. Castoldi E., Rosing J. APC resistance: biological basis and acquired influences. J Thromb Haemost: 2010; 8 3 445 453
152. de Visser M. C., van Hylckama Vlieg A., Tans G., et al. Determinants of the APTT- and ETP-based APC sensitivity tests. J Thromb Haemost: 2005; 3 7 1488 1494 (Pubitemid 41725208)
153. Osterud B. Cellular interactions in tissue factor expression by blood monocytes. Blood Coagul Fibrinolysis: 1995; 6 01 S20 S25
154. Muñoz-Rodríguez F. J., Reverter J. C., Font J., et al. Clinical significance of acquired activated protein C resistance in patients with systemic lupus erythematosus. Lupus: 2002; 11 11 730 735 (Pubitemid 35408078)
155. De Lucia D., De Vita F., Orditura M., et al. Hypercoagulable state in patients with advanced gastrointestinal cancer: evidence for an acquired resistance to activated protein C. Tumori: 1997; 83 6 948 952 (Pubitemid 28090598)
156. Humphries S. E., Panahloo A., Montgomery H. E., Green F., Yudkin J. Gene-environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis. Thromb Haemost: 1997; 78 1 457 461 (Pubitemid 27289284)
157. Zangari M., Saghafifar F., Anaissie E., et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis: 2002; 13 3 187 192 (Pubitemid 35001883)
158. Hoffman R., Haim N., Brenner B. Cancer and thrombosis revisited. Blood Rev: 2001; 15 2 61 67 (Pubitemid 32619559)
159. Schöni R., Quehenberger P., Wu J. R., Wilmer M. Clinical evaluation of a new functional test for detection of activated protein C resistance (Pefakit APC-R Factor V Leiden) at two centers in Europe and the USA. Thromb Res: 2007; 119 1 17 26 (Pubitemid 44716212)
160. Zangari M., Berno T., Zhan F., Boucher K. M., Tricot G., Fink L. Activated protein C resistance as measured by residual factor V after Russell's viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls. Blood Coagul Fibrinolysis: 2011; 22 5 420 423